|
|
Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma |
Tung Huynh1, Ke-Qin Hu2() |
1. Department of Pharmacy, University of California, Irvine, School of Medicine, Orange, CA 92868, USA 2. Division of Gastroenterology and Hepatology, University of California, Irvine, School of Medicine, Orange, CA 92868, USA |
|
|
Abstract Direct acting antiviral (DAA) treatments may reduce the elevated α fetoprotein (AFP), but data on how these treatments affect elevated AFP in patients with chronic hepatitis C (CHC) remain insufficient. In the present study, the frequency of baseline AFP elevations and their related factors, AFP dynamics during and after DAA treatment, and factors associated with AFP reduction was assessed. This retrospective study included 141 patients with CHC without hepatocellular carcinoma who received DAA and achieved sustained virological response. The details are as follows: mean post-treatment follow-up was 99 weeks (12–213); mean age, 57.8 years old; 52%, males; 79%, genotype (GT) 1; and 47%, cirrhosis. Pre-treatment AFP elevation (>5.5 ng/mL) was seen in 48.2% patients. On multivariate analysis, baseline AFP>5.5 was associated with the presence of cirrhosis (P=0.001), co-existing non-alcoholic steatohepatitis (NASH) (P = 0.035), and GT 1 (P = 0.029). AFP normalization was seen in 28.2% patients at treatment week 2, in 52% at the end of treatment, and in 73.4% at the end of follow-up. Post-treatment week 24 AFP normalization was associated with the absence of cirrhosis (P = 0.003), Child--Pugh score<6 (P = 0.015), and baseline AFP<10 (P = 0.015). AFP elevation is common in patients with CHC and independently associated with NASH, cirrhosis, and GT 1. DAA treatment resulted in AFP normalization as early as treatment week 2. Post-treatment week 24 AFP normalization is independently associated with the absence of cirrhosis, Child--Pugh score<6, and baseline AFP<10.
|
Keywords
chronic hepatitis C
α fetoprotein
direct acting antiviral treatment
cirrhosis
|
Corresponding Author(s):
Ke-Qin Hu
|
Just Accepted Date: 04 September 2019
Online First Date: 30 October 2019
Issue Date: 16 December 2019
|
|
1 |
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990−2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385(9963): 117–171
https://doi.org/10.1016/S0140-6736(14)61682-210.1097/MEG.0000000000001400
pmid: 25530442
|
2 |
E Gower, C Estes, S Blach, K Razavi-Shearer, H Razavi. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(1 Suppl): S45–S57
https://doi.org/10.1016/j.jhep.2014.07.027
pmid: 25086286
|
3 |
RL Koretz, KW Lin, JP Ioannidis, J Lenzer. Is widespread screening for hepatitis C justified? BMJ 2015; 350: g7809
https://doi.org/10.1136/bmj.g7809
pmid: 25587052
|
4 |
F Ermis, E Senocak Tasci. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7(17): 2100–2109
https://doi.org/10.4254/wjh.v7.i17.2100
pmid: 26301052
|
5 |
NL Lazarevich. Molecular mechanisms of α-fetoprotein gene expression. Biochemistry (Mosc) 2000; 65(1): 117–133
pmid: 10702646
|
6 |
D Ball, E Rose, E Alpert. α-fetoprotein levels in normal adults. Am J Med Sci 1992; 303(3): 157–159
https://doi.org/10.1097/00000441-199203000-00004
pmid: 1375809
|
7 |
H Matsui, N Rimal, K Kamakura, S Uesugi, H Yamamoto, S Ikeda, K Taketa. Serum α-fetoprotein levels in healthy Japanese adults. Acta Med Okayama 1998; 52(3): 149–154
pmid: 9661742
|
8 |
H Yoshida, Y Shiratori, M Moriyama, Y Arakawa, T Ide, M Sata, O Inoue, M Yano, M Tanaka, S Fujiyama, S Nishiguchi, T Kuroki, F Imazeki, O Yokosuka, S Kinoyama, G Yamada, M Omata. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131(3): 174–181
https://doi.org/10.7326/0003-4819-131-3-199908030-00003
pmid: 10428733
|
9 |
M Sherman. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25(2): 143–154
https://doi.org/10.1055/s-2005-871194
pmid: 15918143
|
10 |
AM Di Bisceglie, JH Hoofnagle. Elevations in serum α-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64(10): 2117–2120
https://doi.org/10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
pmid: 2478280
|
11 |
YF Liaw, DI Tai, TJ Chen, CM Chu, MJ Huang. α-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6(3): 133–137
https://doi.org/10.1111/j.1600-0676.1986.tb00279.x
pmid: 2427909
|
12 |
N Bayati, AL Silverman, SC Gordon. Serum α-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998; 93(12): 2452–2456
https://doi.org/10.1111/j.1572-0241.1998.00703.x
pmid: 9860408
|
13 |
NS Goldstein, DE Blue, R Hankin, S Hunter, N Bayati, AL Silverman, SC Gordon. Serum α-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999; 111(6): 811–816
https://doi.org/10.1093/ajcp/111.6.811
pmid: 10361518
|
14 |
CW Chu, SJ Hwang, JC Luo, CR Lai, SH Tsay, CP Li, JC Wu, FY Chang, SD Lee. Clinical, virologic, and pathologic significance of elevated serum α-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001; 32(3): 240–244
https://doi.org/10.1097/00004836-200103000-00014
pmid: 11246354
|
15 |
KQ Hu, NL Kyulo, N Lim, B Elhazin, DJ Hillebrand, T Bock. Clinical significance of elevated α-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99(5): 860–865
https://doi.org/10.1111/j.1572-0241.2004.04152.x
pmid: 15128351
|
16 |
G Fattovich, G Giustina, F Degos, F Tremolada, G Diodati, P Almasio, F Nevens, A Solinas, D Mura, JT Brouwer, H Thomas, C Njapoum, C Casarin, P Bonetti, P Fuschi, J Basho, A Tocco, A Bhalla, R Galassini, F Noventa, SW Schalm, G Realdi. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112(2): 463–472
https://doi.org/10.1053/gast.1997.v112.pm9024300
pmid: 9024300
|
17 |
Y Sato, K Nakata, Y Kato, M Shima, N Ishii, T Koji, K Taketa, Y Endo, S Nagataki. Early recognition of hepatocellular carcinoma based on altered profiles of α-fetoprotein. N Engl J Med 1993; 328(25): 1802–1806
https://doi.org/10.1056/NEJM199306243282502
pmid: 7684823
|
18 |
MJ Tong, NS el-Farra, AR Reikes, RL Co. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332(22): 1463–1466
https://doi.org/10.1056/NEJM199506013322202
pmid: 7739682
|
19 |
TM Chen, PT Huang, MH Tsai, LF Lin, CC Liu, KS Ho, CP Siauw, PL Chao, JN Tung. Predictors of α-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon α 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007; 22(5): 669–675
https://doi.org/10.1111/j.1440-1746.2007.04898.x
pmid: 17444854
|
20 |
S Murashima, M Tanaka, M Haramaki, S Yutani, Y Nakashima, K Harada, T Ide, R Kumashiro, M Sata. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006; 51(4): 808–812
https://doi.org/10.1007/s10620-006-3211-2
pmid: 16615008
|
21 |
Y Tamura, S Yamagiwa, Y Aoki, S Kurita, T Suda, S Ohkoshi, M Nomoto, Y Aoyagi; Niigata Liver Disease Study Group. Serum α-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2009; 54(11): 2530–2537
https://doi.org/10.1007/s10620-008-0642-y
pmid: 19093203
|
22 |
Y Arase, K Ikeda, F Suzuki, Y Suzuki, M Kobayashi, N Akuta, T Hosaka, H Sezaki, H Yatsuji, Y Kawamura, M Kobayashi, H Kumada. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007; 79(8): 1095–1102
https://doi.org/10.1002/jmv.20866
pmid: 17597485
|
23 |
Y Asahina, K Tsuchiya, N Tamaki, I Hirayama, T Tanaka, M Sato, Y Yasui, T Hosokawa, K Ueda, T Kuzuya, H Nakanishi, J Itakura, Y Takahashi, M Kurosaki, N Enomoto, N Izumi. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52(2): 518–527
https://doi.org/10.1002/hep.23691
pmid: 20683951
|
24 |
Y Asahina, K Tsuchiya, T Nishimura, M Muraoka, Y Suzuki, N Tamaki, Y Yasui, T Hosokawa, K Ueda, H Nakanishi, J Itakura, Y Takahashi, M Kurosaki, N Enomoto, M Nakagawa, S Kakinuma, M Watanabe, N Izumi. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58(4): 1253–1262
https://doi.org/10.1002/hep.26442
pmid: 23564522
|
25 |
Y Tachi, T Hirai, Y Ishizu, T Honda, T Kuzuya, K Hayashi, M Ishigami, H Goto. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. J Gastroenterol Hepatol 2016; 31(5): 1001–1008
https://doi.org/10.1111/jgh.13245
pmid: 27123974
|
26 |
Y Osaki, Y Ueda, H Marusawa, J Nakajima, T Kimura, R Kita, H Nishikawa, S Saito, S Henmi, A Sakamoto, Y Eso, T Chiba. Decrease in α-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol 2012; 47(4): 444–451
https://doi.org/10.1007/s00535-011-0505-8
pmid: 22105231
|
27 |
HB El-Serag, J Kramer, Z Duan, F Kanwal. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat 2016; 23(9): 687–696
https://doi.org/10.1111/jvh.12533
pmid: 27040447
|
28 |
HB El-Serag, F Kanwal, P Richardson, J Kramer. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64(1): 130–137
https://doi.org/10.1002/hep.28535
pmid: 26946190
|
29 |
K Takayama, N Furusyo, E Ogawa, H Ikezaki, M Shimizu, M Murata, J Hayashi. Direct-acting antiviral-based triple therapy on α-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol 2015; 21(15): 4696–4706
https://doi.org/10.3748/wjg.v21.i15.4696
pmid: 25914481
|
30 |
T Oze, N Hiramatsu, T Yakushijin, M Miyazaki, A Yamada, M Oshita, H Hagiwara, E Mita, T Ito, H Fukui, Y Inui, T Hijioka, M Inada, K Katayama, S Tamura, H Yoshihara, A Inoue, Y Imai, E Hayashi, M Kato, T Miyagi, Y Yoshida, T Tatsumi, A Kasahara, T Hamasaki, N Hayashi, T Takehara; Osaka Liver Forum. Post-treatment levels of a-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2014; 12(7): 1186–1195
https://doi.org/10.1016/j.cgh.2013.11.033
pmid: 24321207
|
31 |
K Nguyen, M Jimenez, N Moghadam, C Wu, A Farid, J Grotts, D Elashoff, G Choi, FA Durazo, MM El-Kabany, SB Han, S Saab. Decrease of α-fetoprotein in patients with cirrhosis treated with direct acting agents. J Clin Transl Hepatol 2017; 5(1): 43–49
pmid: 28507926
|
32 |
E Miyaki, M Imamura, N Hiraga, E Murakami, T Kawaoka, M Tsuge, A Hiramatsu, Y Kawakami, H Aikata, CN Hayes, K Chayama. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res 2016; 46(8): 758–764
https://doi.org/10.1111/hepr.12621
pmid: 26574180
|
33 |
R Fouad, A Elsharkawy,, SA, EL Alem, M Kassas, , M Alboraie, A Sweedy, S Afify, Z Abdellatif, M Khairy, G Esmat. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol 2019 Mar 20. [Epub ahead of print]
https://doi.org/10.1097/MEG.0000000000001400
pmid: 30896550
|
34 |
T Huynh, J Zhang, KQ Hu. Hepatitis C virus clearance by direct acting antiviral results in rapid resolution of hepatocytic injury as indicated by both alanine aminotransferase and aspartate aminostransferase normalization. J Clin Transl Hepatol 2018; 6(3): 258–263
https://doi.org/10.14218/JCTH.2018.00014
pmid: 30271737
|
35 |
AM Di Bisceglie, RK Sterling, RT Chung, JE Everhart, JL Dienstag, HL Bonkovsky, EC Wright, GT Everson, KL Lindsay, AS Lok, WM Lee, TR Morgan, MG Ghany, DR Gretch; HALT-C Trial Group. Serum α-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43(3): 434–441
https://doi.org/10.1016/j.jhep.2005.03.019
pmid: 16136646
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|